Übersicht – Möglichkeiten (und Grenzen) der Genexpressionsanalyse

• Literatur

• 1 Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 2011;
• 2 Gluz O, Kreipe HH, Christgen M et al. Prospective comparison of recurrence score and inde-pendent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial. J Clin Oncol 2012; 30: (suppl; abstr 552).
• 3 vanʼt Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical out-come of breast cancer. Nature 2002; 415: 530-536
• 4 Paik S, Shak S, Tang G et al. A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. N Engl J Med 2004; 351: 2817-2826
• 5 Harbeck N, Gluz O, Nitz U. Prädiktive Gensignaturen – Wie valide sind sie?. FORUM. 2015.
• 6 Knauer M, Mook S, Rutgers ET et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010; 120: 655-661
• 7 Krijgsman O, Roepman P, Zwart W et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat 2012; 133: 37-47
• 8 Mamounas EP, Tang G, Fisher B et al. Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor-Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-1683
• 9 Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11: 55-65
• 10 Dubsky P, Brase JC, Jakesz R et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109: 2959-2964
• 11 Poremba C, Uhlendorff J, Pfitzner B et al. Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer. Virchows Arch 2014; 465: 409-417
• 12 Martin M, Brase J, Calvo L, Krappmann K et al. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2 breast cancer patients: results from the GEICAM 9906 trial. Breast Canc Res 2014; 16: R38
• 13 Wolmark N ME, Baehner FL, Butler SM et al. Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. J Clin Oncol 2014; 32 5 s (suppl abstr 11024)
• 14 Simon RM, Paik S, Hayes DF. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. J Natl Canc Inst 2009; 101: 1446-1452
• 15 Eiermann W, Rezai M, Kümmel S et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 2013; 24: 618-624
• 16 Müller BM, Keil E, Lehmann A et al. The EndoPredict Gene-Expression Assay in Clinical Practice – Performance and Impact on Clinical Decisions. PLoS ONE 04/15/received, 05/28/accepted; 8 (6) e68252 PubMed PMID: PMC3694878.
• 17 Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM et al. Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. Breast Canc Res Treat 2014; 145: 697-705
• 18 Rutgers E, Piccart-Gebhart MJ, Bogaerts J et al. The EORTC 10 041/BIG 03–04 MINDACT trial is feasible: Results of the pilot phase. Eur J Can 2011; 47: 2742-2749
• 19 Nitz U, Gluz O, Kates RE et al. Prognostic impact of discordance between different risk assessment tools in early breast cancer (Recurrence Score, Central Grade, Ki67): early outcome analysis from the prospective Phase III WSG-PlanB Trial. San Antonio Breast Cancer Symposium 2014; P4-11–01
• 20 Hofmann D, Nitz U, Gluz O et al. WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multicenter, controlled, non-blinded, randomized, investigator initiated phase II / III trial. Trials 2013; 14: 261